Live Breaking News & Updates on Rckt

Stay informed with the latest breaking news from Rckt on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Rckt and stay connected to the pulse of your community

Rocket Pharmaceuticals (NASDAQ:RCKT) Receives New Coverage from Analysts at The Goldman Sachs Group

The Goldman Sachs Group started coverage on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report published on Tuesday, MarketBeat Ratings reports. The firm issued a neutral rating and a $39.00 price target on the biotechnology company’s stock. RCKT has been the topic of several other reports. UBS Group cut their price objective […]

China , Kinnari-patel , Gotham-makker , Jpmorgan-chase-co , Steward-partners-investment-advisory , Analyst-recommendations-for-rocket-pharmaceuticals , Wells-fargo-company , Life-insurance-co , China-universal-asset-management-co , Rocket-pharmaceuticals-inc , Needham-company , Advisor-group-holdings-inc

China Universal Asset Management Co. Ltd. Raises Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

China Universal Asset Management Co. Ltd. boosted its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 404.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,424 shares of the biotechnology company’s stock after buying an […]

China , Texas , United-states , John-militello , Kinnari-patel , Asset-management-americas-corp , Rocket-pharmaceuticals-price-performance , Securities-exchange-commission , Jpmorgan-chase-co , Allspring-global-investments-holdings , Exchange-commission , China-universal-asset-management-co

China Universal Asset Management Co. Ltd. Buys 8,356 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

China Universal Asset Management Co. Ltd. lifted its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 404.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,424 shares of the biotechnology company’s stock after buying an additional 8,356 shares during the […]

China , Gaurav-shah , Gotham-makker , Rocket-pharmaceuticals-price-performance , Annandale-capital , Goldman-sachs-group , Nasdaq , Jpmorgan-chase-co , China-universal-asset-management-co , Wells-fargo-company , Steward-partners-investment-advisory , Rocket-pharmaceuticals-company-profile

Cantor Fitzgerald Reiterates "Overweight" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They currently have a $65.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 123.91% from the stock’s previous close. […]

Kinnari-patel , Martin-wilson , Synovus-financial-corp , Rocket-pharmaceuticals , Institutional-trading-of-rocket-pharmaceuticals , Securities-exchange-commission , Rocket-pharmaceuticals-inc , Needham-company , Cantor-fitzgerald , Analyst-recommendations-for-rocket-pharmaceuticals , Hightower-advisors , Rocket-pharmaceuticals-stock-down

Rocket Pharmaceuticals' (RCKT) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $65.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 118.93% from the stock’s […]

Martin-wilson , Kinnari-patel , Rocket-pharmaceuticals-inc , Nasdaq , Rocket-pharmaceuticals , Rocket-pharmaceuticals-trading-down , News-ratings-for-rocket-pharmaceuticals-daily , Hedge-funds-weigh-in-on-rocket-pharmaceuticals , Metlife-investment-management , Needham-company , Jpmorgan-chase-co , Cantor-fitzgerald

JPMorgan Chase & Co. Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $50.00

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its target price decreased by research analysts at JPMorgan Chase & Co. from $55.00 to $50.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential […]

China , Gaurav-shah , Martin-wilson , Rocket-pharmaceuticals-stock , Rocket-pharmaceuticals-inc , Jpmorgan-chase-co , News-ratings-for-rocket-pharmaceuticals-daily , Wells-fargo-company , Rocket-pharmaceuticals , Needham-company , Advisor-group-holdings-inc , Life-insurance-co

Clearstead Advisors LLC Sells 862 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Clearstead Advisors LLC decreased its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 29.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,095 shares of the biotechnology company’s stock after selling 862 shares during the period. Clearstead Advisors LLC’s […]

Cantor-fitzgerald , Needham-company , Vanguard-group-inc , Maverick-capital-ltd , Rocket-pharmaceuticals-price-performance , Blackrock-inc , Rocket-pharmaceuticals , Westfield-capital-management-co , Quarter-for-rocket-pharmaceuticals , Nasdaq , Rocket-pharmaceuticals-inc

Clearstead Advisors LLC Reduces Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Clearstead Advisors LLC trimmed its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Free Report) by 29.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 2,095 shares of the biotechnology company’s stock after selling 862 shares during the quarter. Clearstead Advisors LLC’s holdings in Rocket Pharmaceuticals were worth $43,000 at the end of the most […]

China , China-universal-asset-management-co , Needham-company , Clearstead-advisors , Cantor-fitzgerald , Wells-fargo-company , Life-insurance-co , Steward-partners-investment-advisory , News-ratings-for-rocket-pharmaceuticals-daily , Nasdaq , Rocket-pharmaceuticals-inc

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Buy" from Brokerages

Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have been assigned an average rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have issued a report on the […]

Blackrock , New-zealand-general- , New-zealand , Wellington , Needham-company , Analyst-recommendations-for-rocket-pharmaceuticals , Westfield-capital-management-co , News-ratings-for-rocket-pharmaceuticals-daily , Rocket-pharmaceuticals-price-performance , Rocket-pharmaceuticals-inc , Wellington-management-group

FDA Extends Review of Rocket Pharma's Proposed Kresladi

By Colin Kellaher Rocket Pharmaceuticals on Tuesday said the U.S. Food and Drug Administration has extended its review of the biotechnology company's...

Colin-kellaher , Drug-administration , Rocket-pharmaceuticals-on , Article-normal , Pharmaceuticals , Healthcare-life-sciences , Aerospace-defense , Specialized-drugs-medications , Industrial-goods , Regulation-government-policy , New-products-services , Product-service-approvals